Get the Stockscreener App
2.925
22.82%
-0.865
After Hours:
2.97
0.045
+1.54%
Cytek Biosciences Inc stock is traded at $2.925, with a volume of 2.22M.
It is down -22.82% in the last 24 hours and down -21.79% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$3.79
Open:
$3.1
24h Volume:
2.22M
Relative Volume:
2.76
Market Cap:
$492.53M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-32.50
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
-24.22%
1M Performance:
-21.79%
6M Performance:
-58.51%
1Y Performance:
-52.82%
1-Day Range:
$2.865
$3.47
1-Week Range:
$2.865
$3.89
52-Week Range:
$2.865
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
2.925 | 492.53M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Call Transcript - Insider Monkey
Dimensional Fund Advisors LP Grows Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cytek Biosciences: Earnings Call Reveals Mixed Fortunes - TipRanks
Cytek Biosciences stock rating cut, price target drops to $4 By Investing.com - Investing.com Canada
TD Cowen Downgrades Cytek Biosciences to Hold From Buy, Adjusts Price Target to $4 From $7 - marketscreener.com
Cytek Biosciences (CTKB) Downgraded to Hold as Challenges Persist | CTKB Stock News - GuruFocus
Cytek Biosciences Faces Revenue Challenges and Market Uncertainty, Downgraded to Hold - TipRanks
Cytek Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Cytek Biosciences Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Cytek Biosciences misses Q1 2025 earnings forecasts - Investing.com
Cytek Biosciences, Inc. SEC 10-Q Report - TradingView
Cytek Biosciences (CTKB) Reports Q1 Revenue Below Expectations | CTKB Stock News - GuruFocus
What To Expect From Cytek Biosciences Inc (CTKB) Q1 2025 Earnings - Yahoo Finance
Raymond James Financial Inc. Invests $765,000 in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued? (NASDAQ:CTKB) - Seeking Alpha
Wells Fargo & Company MN Acquires 15,516 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Barclays PLC Purchases 14,065 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek BioSciences Inc (NASDAQ: CTKB) Up 4.32%: This Is What Analysts Are Now Forecasting - Stocksregister
XTX Topco Ltd Trims Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Invesco Ltd. - Defense World
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025 - GlobeNewswire
Revolutionary Cell Analysis Technology Takes Center Stage: Cytek's FSP Debuts at CYTO & IMMUNOLOGY2025 - Stock Titan
Why Cytek Biosciences Should Beat Q1 Earnings Expectations - Seeking Alpha
Analysts Predict Cytek BioSciences Inc (NASDAQ:CTKB) To Reach 8 In 12 Months - Marketing Sentinel
Russell Investments Group Ltd. Has $180,000 Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Market Insights: Cytek BioSciences Inc (CTKB)’s Notable Gain of 1.33, Closing at 3.82 - DWinneX
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
Cytek Biosciences to Announce Q1 2025 Financial Results and Host Webcast on May 8, 2025 - Nasdaq
Cytek Biosciences Q1 2025 Earnings: Key Financial Updates Coming May 8What to Watch - Stock Titan
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt? - simplywall.st
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Decreases Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes $131,000 Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences stock hits 52-week low at $3.51 amid market challenges - Investing.com
Trading (CTKB) With Integrated Risk Controls - news.stocktradersdaily.com
Prudential Financial Inc. Has $1.13 Million Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Raymond James Financial Inc. Buys New Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Thrivent Financial for Lutherans Sells 3,001 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cell Analyzer | Cytek Biosciences Inc. | Products - Photonics Spectra
106,597 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Purchased by Teacher Retirement System of Texas - Defense World
Proficio Capital Partners LLC Invests $71,000 in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences stock hits 52-week low at $3.99 amid market shifts - Investing.com India
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by PNC Financial Services Group Inc. - Defense World
Cytek Biosciences expands cell analysis offerings with the affordable, user-friendly Cytek Muse Micro System - SelectScience
Charles Schwab Investment Management Inc. Increases Stock Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Up 2.2% – What’s Next? - Defense World
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):